• Skip to main content
  • Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

Menu
  • HOME
  • ABOUT
    • Close
    • COMPANY OVERVIEW
    • MANAGEMENT
    • BOARD OF DIRECTORS
  • AREAS OF FOCUS
    • Close
    • PIPELINE
    • POSTERS & PUBLICATIONS
    • LEGACY PIPELINE ASSETS
  • INVESTOR RELATIONS
    • Close
    • OVERVIEW
    • ANNUAL GENERAL MEETING
    • CORPORATE GOVERNANCE
      • Close
      • GOVERNANCE OVERVIEW
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIAL INFORMATION
      • Close
      • SEC FILINGS
      • ANNUAL REPORTS
    • NEWS & PRESENTATIONS
      • Close
      • PRESS RELEASES
      • PRESENTATIONS
    • STOCK INFORMATION
      • Close
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
    • EMAIL ALERTS
  • PRESS
    • Close
    • PRESS RELEASES
    • STORIES
  • CONTACT US

Press Release

Akari TX / May 29, 2025

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic products and advanced clinical …

[Read more...] about Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

Akari TX / May 22, 2025

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Live webcast on Thursday, May 29th at 2:20 PM ET BOSTON and LONDON – May 22, 2025 – Akari Therapeutics, Plc …

[Read more...] about Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Akari TX / May 15, 2025

Akari Therapeutics Reports First Quarter 2025 Financial Results and Prov­ides Corporate Update

Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with …

[Read more...] about Akari Therapeutics Reports First Quarter 2025 Financial Results and Prov­ides Corporate Update

Akari TX / May 1, 2025

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development – Oncology

Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record …

[Read more...] about Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development – Oncology

Akari TX / April 22, 2025

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video hereBOSTON and LONDON – …

[Read more...] about Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Next Page »

Footer

Follow Us

Terms of Use
Privacy Statement
Contact Us

Akari TX

Copyright © 2025 · Akari Therapeutics · Site Designed by Polus Digital, Inc.